MARY BARBA: Open Payments
NPI 1447659370 · RIVERSIDE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$733 in 36 payments from 13 companies in 2025. Trend: 2023 $283 · 2024 $404 · 2025 $733
Food & beverage: $733
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 10 | $165 |
| Astellas Pharma US Inc | 3 | $84 |
| Corcept Therapeutics | 4 | $82 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $73 |
| Xeris Pharmaceuticals, Inc. | 3 | $54 |
| ABBVIE INC. | 3 | $52 |
| Amgen Inc. | 2 | $50 |
| Abbott Laboratories | 2 | $46 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $44 |
| SANOFI PASTEUR INC. | 1 | $24 |
Products named: Wegovy, Veozah, Korlym, JARDIANCE, GVOKE HYPOPEN, QULIPTA, FREESTYLE LIBRE 3, XIFAXAN.
Industry payments across CA — which companies pay providers there.
